scholarly journals Thrombocytosis and thrombocytopenia are markers of poor outcome in pediatric patients with community-acquired pneumonia

2019 ◽  
Author(s):  
Huiming Sun ◽  
Shuxiang Li ◽  
Canhong Zhu ◽  
Yongdong Yan ◽  
Yuqing Wang ◽  
...  
Keyword(s):  
Platelet Count ◽  
Pediatric Patients ◽  
Laboratory Data ◽  
Community Acquired Pneumonia ◽  
Multivariate Logistic Regression Model ◽  
Respiratory Complications ◽  
Reactive Protein ◽  
Normal Platelet Count ◽  
Normal Platelet ◽  
Length Of Hospitalization

Abstract Abstract Background: This study aimed to investigate the prevalence of thrombocytopenia and thrombocytosis in hospitalized pediatric patients with community-acquired pneumonia (CAP), and determine whether thrombocytopenia and thrombocytosis are associated with patient outcome. Methods: A total of 9,372 consecutive patients, who were 1-168 months old, diagnosed with CAP and admitted in the Children’s Hospital of Soochow University, were enrolled in the present retrospective observational study. Their clinical and laboratory data were collected. According to the platelet count on admission, these patients were divided into three groups: thrombocytopenia, normal platelet count, and thrombocytosis groups. The clinical characteristics and etiologic pathogens were compared among these groups. The multivariate logistic regression model was applied to identify risk factors for severe CAP, length of hospitalization ≥10 days and respiratory complications. The correlations between platelet count and clinical features were determined by Spearman’s correlation. Results: Thrombocytosis and thrombocytopenia were found in 3,376 (36.0%) and 43 (0.5%) patients, respectively. Normal platelet count was observed in 5,953 (63.5%) patients. Thrombocytopenia was an independent risk factor of severe CAP (OR, 6.206; 95% CI, 2.209-17.436; P=0.001), while thrombocytosis was associated with length of hospitalization of ≥10 days (OR, 1.315; 95% CI, 1.177-1.470; P<0.001). In addition, thrombocytosis was associated with respiratory complications (OR, 1.658; 95% CI, 1.171-2.346; P=0.004). Platelet count (median 350.0 [IQR 270.2-447.0] × 109/L) was positively correlated with length of hospitalization (median 7.0 [IQR 6.0-9.0] days) (r = 0.101, P<0.001), but negatively correlated with age (median 12.0 [IQR 3.0-36.0] months) (r = -0.401, P<0.001) and C-reactive protein (median 2.0 [IQR 0.3-10.7] mg/dl) (r = -0.191, P<0.001). Conclusion: Thrombocytosis is highly prevalent, while thrombocytopenia has low prevalence in pediatric CAP patients. Both thrombocytosis and thrombocytopenia are associated with clinical outcomes in pediatric CAP patients.

The implications of platelet count changes during hospitalization in the disease management of pediatric patients with bronchiolitis

2019 ◽  
Author(s):  
Huiming Sun ◽  
Hua Xu ◽  
Ting Wang ◽  
Yongdong Yan ◽  
Wei Ji ◽  
...  
Keyword(s):  
Platelet Count ◽  
Disease Management ◽  
Oxygen Therapy ◽  
Pediatric Patients ◽  
Pediatric Intensive Care ◽  
Reactive Protein ◽  
Normal Platelet ◽  
Group A ◽  
Group B ◽  
Admission Group

Abstract Background: The clinical implications of platelet count changes in patients with bronchiolitis throughout hospitalization have not been extensively investigated. We aimed to investigate the significance of platelet count on admission and platelet count changes during hospitalization in pediatric patients with bronchiolitis. Methods: Clinical data from 559 consecutive patients hospitalized for bronchiolitis were collected and compared after grouping according to the platelet count on admission and the delta platelet count during hospitalization (the platelet count on discharge minus the platelet count on admission; Group A, delta platelet count ≤ -50 × 109/L; Group B, -50 × 109/L < delta platelet count ≤ 50 × 109/L; Group C, delta platelet count > 50 × 109/L). Results: Thrombocytosis was found in 122 (21.8%) patients, while 437 (78.2%) patients had a normal platelet count on admission. There was no difference in disease severity between these two groups. Groups A, B, and C comprised 79 (14.1%), 179 (32.0%), and 301 (53.9%) patients, respectively. The patients from Group A had a higher platelet count on admission, a lower platelet count on discharge, and a longer hospitalization duration. These patients had a lower concentration of C-reactive protein, longer periods of oxygen therapy and stay in the pediatric intensive care unit (PICU), and a greater frequency of mechanical ventilation than the patients from Group B or Group C. Notably, among all the patients, the delta platelet count [63 (-3–142) × 109/L] negatively correlated with the numbers of days of oxygen therapy [4.0 (3.0–6.0), day] (r = -0.186, P = 0.027) and stay in the PICU [5.0 (3.0–6.0), day] (r = -0.391, P = 0.001). Conclusions: Repeated assessment of platelet count during hospitalization in pediatric patients with bronchiolitis may provide useful information for disease management.

Cancer incidence in patients with a high normal platelet count: a cohort study using primary care data

2018 ◽  
Vol 35 (6) ◽  
pp. 671-675 ◽  
Author(s):  
Emily Ankus ◽  
Sarah J Price ◽  
Obioha C Ukoumunne ◽  
William Hamilton ◽  
Sarah E R Bailey
Keyword(s):  
Primary Care ◽  
Cohort Study ◽  
Platelet Count ◽  
Cancer Incidence ◽  
Normal Platelet Count ◽  
Normal Platelet ◽  
Primary Care Data

scholarly journals Regulation of megakaryocyte ploidy in vivo in the rat

Blood ◽  
1990 ◽  
Vol 75 (1) ◽  
pp. 74-81 ◽  
Author(s):  
DJ Kuter ◽  
RD Rosenberg
Keyword(s):  
Platelet Count ◽  
Feedback Loop ◽  
Antiplatelet Antibody ◽  
Normal Platelet Count ◽  
Normal Platelet ◽  
Plasma Factor ◽  
Ploidy Changes ◽  
The Relationship ◽  
Made In

Abstract The relationship between the bone marrow (BM) megakaryocyte and the circulating platelet was explored. Incremental changes in platelet count were made in rats by infusion of antiplatelet antibody or by platelet transfusion, and the response of megakaryocytes was measured by flow cytometry. Proportional changes in megakaryocyte ploidy were demonstrated: As the platelet count declined, ploidy increased; as the platelet count increased, ploidy decreased. Even moderate degrees of thrombocytopenia and thrombocytosis (48% and 177% of the normal platelet count) were associated with changes in ploidy. These changes were not the results of the technique used to alter the platelet count because reinfusion of platelets after 3 hours of thrombocytopenia prevented any ploidy change. These studies proved that the circulating platelet and the megakaryocyte constitute a classic feedback loop whose activity can be measured by the degree of ploidization of the megakaryocyte. The minimal duration of thrombocytopenia necessary to promote megakaryocyte ploidy changes was approximately 10 hours. Using a BM culture assay, we identified a plasma factor which induced alterations in megakaryocyte ploidy and whose level is inversely proportional to the platelet count.

scholarly journals Phospholipid Accumulation in Histiocytes of Splenic Pulp Associated with Thrombocytopenic Purpura

Blood ◽  
1961 ◽  
Vol 18 (1) ◽  
pp. 73-88 ◽  
Author(s):  
SIDNEY L. SALTZSTEIN
Keyword(s):  
Bone Marrow ◽  
Platelet Count ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Lipid Accumulation ◽  
Thrombocytopenic Purpura ◽  
Normal Platelet Count ◽  
Normal Platelet

Abstract Accumulation of a lipid, histochemically a phospholipid, in the histiocytes of the splenic pulp was observed in seven patients with thrombocytopenic purpura. Six had classical idiopathic thrombocytopenic purpura with abundant megakaryocytes in the bone marrow. Splenectomy resulted in clinical and hematologic remissions in four of these six, continued thrombocytopenia in the fifth, and in the continued requirement of corticosteroid to maintain a reasonably normal platelet count in the sixth. The seventh patient, who died shortly after splenectomy, had marked hypoplasia of megakaryocytes. Similar lipid accumulation was not seen in more than 700 other spleens, removed for a variety of reasons, reviewed in this study. Platelet phagocytosis has been suggested as a source of the lipid.

Idiopathic, asymptomatic thrombocytopenia in Cavalier King Charles spaniels: 11 cases (1983-1993)

1997 ◽  
Vol 33 (5) ◽  
pp. 411-415 ◽  
Author(s):  
LE Smedile ◽  
DM Houston ◽  
SM Taylor ◽  
K Post ◽  
GP Searcy
Keyword(s):  
Platelet Count ◽  
Data Base ◽  
Medical Records ◽  
Immunosuppressive Drugs ◽  
Medical Data ◽  
Giant Platelets ◽  
Normal Platelet Count ◽  
Normal Platelet ◽  
Purdue University

The medical records of 11 Cavalier King Charles spaniels with idiopathic, asymptomatic thrombocytopenia and large-to-giant platelets were identified from a 10-year retrospective search using the Veterinary Medical Data Base at Purdue University. Eight of the dogs had been treated with various immunosuppressive drugs. Six of the treated dogs remained thrombocytopenic, one was not reevaluated, and one developed a normal platelet count. The underlying etiology of idiopathic, asymptomatic thrombocytopenia in Cavalier King Charles spaniels has not been identified, but this condition could represent a congenital macrothrombocytopenic disorder.

ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2895-2895
Author(s):  
Gail A. Rock ◽  
David Anderson ◽  
Barrett Benny ◽  
David Barth ◽  
William Clark ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Enzyme Activity ◽  
Platelet Count ◽  
Plasma Exchange ◽  
Protein S ◽  
Inhibitor Activity ◽  
Thrombocytopenic Purpura ◽  
Normal Platelet Count ◽  
Normal Platelet ◽  
Alternative Solutions

Abstract Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate randomized prospective sample trials. However, it is intellectually appealing. Additionally, the use of the ADAMTS 13 level either to predict disease or outcome has not been resolved. Methods Cryosupernatant plasma (CSP) was compared to solvent detergent treated plasma (SDP) over one cycle (nine days) of plasma exchange (PE) and subsequent procedures as required. Throughout treatment, ADAMTS 13 and protein S levels were followed. Results At the primary end point of one month, 3 of 35 of the CSP and 1 of 27 of the SDP patients died. The average platelet count was 184 × 109 per litre for CSP and 209 × 109 per litre for SDP. While vWF and FVIII were elevated in all patients at entry, no unusually large vWF multimers were seen at any time. At entry 9 patients had ≤ 0–10% ADAMTS 13 and 14 of 62 had normal levels with the rest in between. At presentation only 9 patients had 100% inhibitor activity with no inhibitor in 18 patients. Of the four patients who died, two who received CSP, had 100% enzyme activity at presentation whereas one had no ADAMTS-13 and another had 10%. All 4 patients died within 10 days. Fifteen patients with less than 10% enzyme activity had >1.5 vWF. However, elevated (>3u/mL) vWF was seen in the presence of normal ADAMTS-13 levels. Six months after remission, and in the presence of a normal platelet count, ADAMTS13 remained low in 5 patients and normal in 15.Protein S levels in 41/62 patients studied showed little variation during therapy with values on day 3 and 5, similar to those seen on entry. Conclusion In idiopathic TTP, ADAMTS 13 levels do not correlate with disease, and are not predictive of outcome. While protein S levels in the SDP were lower than those found in FFP, this did not appear to have clinical significance.

Preoperative thrombocytosis as a predictor of unfavorable survival in resectable non-small cell lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e18531-e18531
Author(s):  
Jiwen Wang ◽  
Min Luo ◽  
Hanmo Wu ◽  
Liming Sheng ◽  
Dan Su ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Platelet Count ◽  
Small Cell Lung Cancer ◽  
Disease Progression ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Platelet Counts ◽  
Normal Platelet Count ◽  
Normal Platelet

e18531 Background: Activated platelet is thought to promote cancer cells growth and metastasis, playing an important role in progression of cancer. However, the association between platelet counts and prognosis of patient with non small cell lung cancer (NSCLC) had not been fully elucidated. The aim of this study is to investigate the prognostic value of platelet counts in resectable NSCLC. Methods: A total of 636 primary NSCLC patients who had curatively resected surgery in Zhejiang Cancer Hospital from November 2006 to January 2011 were retrospectively analyzed. Preoperative platelet counts and clinicopathological factors were collected from the medical record database. Patients were followed up for disease progression free survival (PDS) and overall survival (OS) until January 20, 2013. The association between platelet counts and patients’ outcome were evaluated. Results: In all patients, 13.8% (88/636) had increased platelet count (>300 × 109/L), referred to as thrombocytosis. The proportion of thrombocytosis was significantly higher in male, squamous-cell carcinoma and stage III than that in female, other histological types and early stage NSCLC. Moreover, thrombocytosis was associated with significantly shortened survival. Multivariate Cox analysis showed patient with thrombocytosis not only had a 1.66 time elevated risk for disease progression (95% CI, 1.14-2.41, p=0.009), but also had and a 1.47 time risk for death (95% CI, 1.04-2.08, P=0.029), compared with that in those having normal platelet count. More interestingly, the risk for replase was increased to 3.19 times (95% CI, 1.41-7.23, p=0.006) in stage I NSCLC with thrombocytosis than that in patients with normal platelet count after stratified analysis by stage. Conclusions: Preoperative platelet count is an independent prognostic predictor in operable NSCLC, especially in early stage I NSCLC. Platelet count may serve as a useful indicator and potential target for personalized treatment with antiplatelet reagent.

ABNORMAL HEMORRHAGE WITH NORMAL PLATELET COUNT AND NORMAL CLOTTING

1948 ◽  
Vol 49 (4) ◽  
pp. 641-646 ◽  
Author(s):  
Russell L. Haden ◽  
R. H. Schneider ◽  
Lee C. Underwood
Keyword(s):  
Platelet Count ◽  
Normal Platelet Count ◽  
Normal Platelet

scholarly journals Thrombocytopenia inPlasmodium vivaxMalaria: How Significant?

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Arti Muley ◽  
Jitendra Lakhani ◽  
Saurabh Bhirud ◽  
Abhinam Patel
Keyword(s):  
Platelet Count ◽  
Serum Creatinine ◽  
Vivax Malaria ◽  
Severe Disease ◽  
Lung Involvement ◽  
Ventilator Support ◽  
Altered Sensorium ◽  
Normal Platelet Count ◽  
Normal Platelet ◽  
Hematological Profile

Introduction. Thrombocytopenia is frequently noticed withP. falciparummalaria but is less reported and studied withP. vivax.Materials and Methods. The study was conducted in the Department of Medicine, SBKS MI & RC, Pipariya. We included patients who were diagnosed with vivax malaria. The data regarding their clinical and hematological profile was collected and analysed.Result. A total of 66 patients were included. 42 (63%) had platelet count <100000/mm3. Mean platelet count was 1,18,650, range being 8000/mm3–6,10,000/mm3. Amongst those with thrombocytopenia, 16 (38.09%) had anemia, 14 (33.33%) had serum creatinine >1.2 gm/dL, 15 (35.71%) had jaundice (s. bilirubin > 1.2), 2 (4.76%) had altered sensorium, 6 (14.28%) had ARDS, 2 needed ventilator support, and 1 expired. Amongst those with normal platelet count, 5 (20.83%) had anemia and 1 had jaundice whereas none had elevated s. creatinine, altered sensorium, or lung involvement.Conclusion. Thrombocytopenia is now being seen more commonly with vivax malaria. Patients with platelet count <1 lac/cumm have more severe disease.

Sign in / Sign up

Export Citation Format

Share Document